Catalog 01 Resources 02 How to order 03 CalculatorBlog Cart 03 Home 04
Metabolic & GLP-1

Tirzepatide Australia — GIP/GLP-1 Reference Material

Tirzepatide research peptide vial — TXLABS, ≥98% HPLC

From $49 AUD · ≥98% HPLC purity · third-party COA · ships Australia-wide

What is Tirzepatide?

Tirzepatide is a synthetic dual GIP and GLP-1 receptor agonist (a unimolecular incretin peptide). It has been investigated in research on incretin receptor signalling, insulin secretion, glucose regulation and energy-metabolism pathways. Tirzepatide is a reference material in metabolic and receptor-pharmacology studies.

Specifications

What the research covers

Tirzepatide is a synthetic 39-residue peptide characterised in the literature as a dual agonist at two class B G-protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). PubChem lists its molecular formula as C225H348N48O68 with a molecular weight near 4813 Da. Unlike semaglutide and liraglutide, which are built on the GLP-1 backbone, tirzepatide's sequence is derived from native GIP, and its affinity for the GLP-1 receptor is engineered rather than inherited. Two alpha-aminoisobutyric acid residues confer resistance to dipeptidyl peptidase-4 cleavage, and a C20 fatty diacid attached through a linker to a lysine side chain drives reversible albumin binding, which is the structural basis for the extended circulating half-life reported for the molecule.

The mechanistic literature on tirzepatide is unusually detailed for a peptide of this age. Published receptor pharmacology has compared its potency and efficacy at GIPR and GLP-1R, and has described a signalling profile at the GLP-1 receptor that is imbalanced relative to native GLP-1, with beta-arrestin recruitment weaker in proportion to cAMP accumulation. Whether that imbalance explains anything observed downstream remains an open question in the literature rather than a settled account. Preclinical work has examined GIP receptor biology in adipose tissue and in the central nervous system, an area that was comparatively neglected before dual agonists made it relevant again. Large randomised clinical trial programmes in type 2 diabetes and in obesity have been reported since 2021.

In Australia tirzepatide is registered on the Australian Register of Therapeutic Goods as MOUNJARO, sponsored by Eli Lilly Australia, with pre-filled pen entries registered from December 2022 and vial entries from July 2023. It is a prescription medicine. TXLABS supplies tirzepatide only as an analytical reference material for laboratory work: method qualification, LC-MS identity confirmation, receptor pharmacology and stability studies. It is not supplied for human or veterinary administration and nothing here describes therapeutic use.

Reading the certificate

For a large acylated peptide, a purity percentage on its own answers very little. The species that matter are des-acyl tirzepatide, in which the fatty diacid has been lost, and deletion sequences from incomplete coupling across 39 residues; both can chromatograph close to the parent on reversed-phase HPLC while being different molecules. Identity should therefore be established by mass spectrometry against the expected mass near 4813 Da, and the assay should be reported in milligrams against the vial's label weight rather than as a percentage alone. TXLABS publishes third-party certificates for its tested lots in the CoA library. No certificate is currently published for tirzepatide, and this page does not claim one. The certificate covering the specific lot supplied is available on request to support@txlabs.bio.

Storage and handling

Lyophilised tirzepatide is held at -20 °C for long-term storage, desiccated and protected from light, with 2-8 °C adequate for material in active use. The fatty diacid makes the molecule amphiphilic, so it accumulates at air-liquid interfaces and can aggregate under shear: add diluent slowly down the inner wall of the vial, rotate gently, and do not vortex or shake. Visible foaming is the signal that interface stress has occurred. Equilibrate a frozen vial to room temperature before breaking the seal, because condensation on cold glass wets a hygroscopic cake. Reconstituted solution is kept at 2-8 °C and shielded from light; if a portion must be frozen, aliquot into single-use volumes rather than cycling one vial. Australian transit is where most avoidable damage occurs. Summer road freight and unattended letterboxes routinely exceed 40 °C, and the larger acylated peptides have less thermal headroom than short sequences. Collect parcels promptly and refrigerate on arrival.

Working out concentration

Concentration is mass divided by diluent volume, nothing more. A 10 mg tirzepatide vial reconstituted with 1 mL of bacteriostatic water gives 10 mg/mL; with 2 mL, 5 mg/mL. A 30 mg vial with 3 mL also gives 10 mg/mL, and a 120 mg vial with 4 mL gives 30 mg/mL. The TXLABS range spans 10 mg to 120 mg per vial, a twelvefold spread, so an identical diluent volume produces wildly different concentrations across the catalogue and the arithmetic is worth writing down rather than assuming. At 4813 Da, a 10 mg/mL solution corresponds to roughly 2.1 mM. The reconstitution calculator resolves any vial and volume pairing. Worked concentration examples only, not a protocol.

How it relates to adjacent compounds

Tirzepatide sits between the single-receptor and triple-receptor ends of the incretin group in this catalogue. Semaglutide is a GLP-1 receptor agonist built on the GLP-1 backbone; retatrutide adds glucagon receptor agonism to the GIP and GLP-1 activities on a glucagon/GIP scaffold. Tirzepatide differs from both in being built on native GIP rather than GLP-1, which is a genuine difference in design lineage and not a statement about relative effect. Cagrilintide is often stored alongside these but belongs to the amylin family and acts through calcitonin receptor complexes, a separate receptor system entirely. The practical consequence in a laboratory holding several of them is that none can stand in as a system-suitability standard for another, despite the shared design vocabulary. These are structural and receptor-level relationships only.

Frequently asked questions

What is tirzepatide, structurally? +
A synthetic 39-residue peptide with the formula C225H348N48O68 and a molecular weight near 4813 Da. Its backbone derives from native glucose-dependent insulinotropic polypeptide rather than GLP-1, it carries two alpha-aminoisobutyric acid residues that block dipeptidyl peptidase-4 cleavage, and a C20 fatty diacid on a lysine side chain promotes albumin binding.
How does a dual agonist differ structurally from a GLP-1 analogue? +
The difference is which parent hormone the sequence starts from. Semaglutide and liraglutide are modified GLP-1; tirzepatide is modified GIP that has been engineered to also engage the GLP-1 receptor. That means the two families are not variations on a theme but different scaffolds, with different masses, different chromatographic behaviour and different impurity profiles.
Is tirzepatide approved in Australia? +
Yes, as a prescription medicine. Tirzepatide is registered on the Australian Register of Therapeutic Goods as MOUNJARO, sponsored by Eli Lilly Australia, with pre-filled pen entries registered from December 2022 and vial entries from July 2023. That registration applies to the approved medicine, not to laboratory reference material, and the TGA has published safety information covering medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists.
Why does vial size matter so much for this product? +
Because TXLABS stocks tirzepatide from 10 mg to 120 mg, a twelvefold range, and concentration is simply mass divided by volume. The same 2 mL of diluent produces 5 mg/mL in the smallest vial and 60 mg/mL in the largest. Recording the vial mass alongside the diluent volume is the only way that number stays reconstructable later.
What is meant by biased signalling in the tirzepatide literature? +
Published receptor pharmacology has reported that at the GLP-1 receptor, tirzepatide produces cAMP accumulation more readily than beta-arrestin recruitment, in contrast to the balanced response native GLP-1 gives. That is a description of assay behaviour. Whether it accounts for anything observed at the whole-organism level is still argued over rather than established.
Why is this material not the same thing as the registered medicine? +
A registered medicine is a specific formulation, made under licensed conditions, with an assessed dossier covering safety, quality and efficacy, supplied through regulated channels. A reference material is characterised powder supplied for analytical work. They are not interchangeable in any sense, and TXLABS supplies the latter only, for in vitro and laboratory research.
How should a tirzepatide solution be handled to avoid aggregation? +
Add diluent slowly down the inner wall of the vial, swirl rather than shake, and avoid vortexing entirely. Acylated peptides partition to air-liquid interfaces, where shear can unfold molecules and nucleate aggregation that later shows up as haze, particulates or a falling assay. Foaming during reconstitution is the visible warning that this has happened.

Related compounds

Browse full catalog Reconstitution calculator